1. Scrip

Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo

 
• By Emily Hayes

Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.

shelves

Results from the VERTIS SITA2 study support a combination of Merck & Co. Inc./Pfizer Inc.'s SGLT-2 inhibitor ertugliflozin with the first-in-class DPP-4 inhibitor Januvia that could prove attractive in type 2 diabetes, despite the crowded nature of the market.

Merck and Pfizer announced positive results from the study at the European Association for the Study of Diabetes meeting in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

KalVista’s Delayed FDA Approval In HAE Comes Through

 
• By Joseph Haas

KalVista’s Ekterly obtains US approval as the first oral, on-demand therapy for hereditary angioedema. It will compete with established injectables.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By Kevin Grogan

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.